Peptide therapies, especially GLP-1 agonists for diabetes and obesity, are gaining popularity beyond medical use. While medically beneficial, their misuse as lifestyle drugs through unregulated online markets raises health risks. India must strengthen CDSCO regulation and awareness to balance innovation, safety, and responsible use.
Click to View More
© 2026 iasgyan. All right reserved